The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).
The COVID-19 pandemic has presented a global challenge. Patients with rheumatic diseases – requiring lifelong immunosuppressants— are at high risk for respiratory and viral infections.
CreakyJoints will present 11 posters and two oral presentations at ACR 2021. Data was derived from their large patient database and Arthritis Power Research Registry. COVID-19 research revealed significantly high levels of anxiety, anger, depression, and social isolation, which we
Post-pandemic structured surveys and interviews with rheumatology patients suggests they may prefer for face-to-face consultations, as telehealth visits run the risk of diagnostic inaccuracies and safety concerns.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a t
Dr. Jack Cush reviews the news and journal articles from the past week and discusses parent-child rheumatologists pairs.
Healthcare is a personal and individualized relationship between a provider and patient. Each patient is treated according to their particular symptoms and personal health characteristics.
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Registry level data of patients with immune-mediated inflammatory diseases (IMIDs) diagnosed with COVID-19 should continue their TNF inhibitor (TNFi) therapy as such patients were less likely to experience adverse COVID-19 outcomes (compared to other immunomodulatory treatments).
Dr. Jack Cush reviews the FDA approvals, news and the latest journal articles from the past week on RheumNow.com.
EULAR has updated its recommendations (points to consider - PtC) for rheumatologists managing patients during COVID-19; now with 2 overarching principles and 12 PtC.
Both systemic onset juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease are acquired autoinflammatory disorders of uncertain etiology. Yet recent reports of AOSD onset and flare following COVID-19 vaccinations may have important mechanistic implications.
Eric Dein @ericdeinmd ( View Tweet )
Leonard Calabrese @LCalabreseDO ( View Tweet )
TheDaoIndex @KDAO2011 ( View Tweet )
Catherine Sims, MD @DrCassySims ( View Tweet )
Links:
Dr. John Cush @RheumNow ( View Tweet )
Links:
